Latest News

  • Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference Read More
  • Alkermes Completes Acquisition of Rodin Therapeutics Read More
  • Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Read More

Investors

ALKS investor relations
Learn more Learn More

Pipeline

patient focused CNS disorder treatments
See Our Approach See Our Approach

Working at Alkermes

career opportunities at Alkermes
Working at Alkermes Join Our Team